Jazz Pharmaceuticals (EUSA Pharma USA) Inc. Sustainability Profile
Jazz Pharmaceuticals (EUSA Pharma USA) Inc., headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative treatments for patients with rare diseases and complex conditions. Founded in 2003, the company has achieved significant milestones, including strategic acquisitions that have expanded its portfolio and market reach. With a focus on neurology and oncology, Jazz Pharmaceuticals offers a range of unique products designed to address unmet medical needs. Their commitment to research and development has positioned them as a leader in the field, particularly with therapies that enhance patient quality of life. Notable achievements include a strong market presence and recognition for their contributions to advancing healthcare solutions.
DitchCarbon Score
How does Jazz Pharmaceuticals (EUSA Pharma USA) Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jazz Pharmaceuticals (EUSA Pharma USA) Inc.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jazz Pharmaceuticals (EUSA Pharma USA) Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures in kg CO2e. The company is a current subsidiary of Jazz Pharmaceuticals plc, which may influence its climate commitments and emissions reporting. While there are no documented reduction targets or specific climate pledges from Jazz Pharmaceuticals (EUSA Pharma USA) Inc., emissions data may be inherited from its parent company, Jazz Pharmaceuticals plc. The emissions data cascaded from the parent organization could provide insights into the broader corporate climate strategy, although specific figures and targets are not detailed in the available information. As a subsidiary, Jazz Pharmaceuticals (EUSA Pharma USA) Inc. may align its sustainability efforts with the initiatives of its parent company, which could include participation in frameworks such as the Carbon Disclosure Project (CDP). However, without explicit data or commitments from the subsidiary level, it is challenging to assess its individual climate impact or reduction strategies. In summary, while Jazz Pharmaceuticals (EUSA Pharma USA) Inc. does not currently report specific emissions data or reduction targets, its climate commitments may be influenced by the broader strategies of its parent company, Jazz Pharmaceuticals plc. Further information would be required to provide a comprehensive overview of its carbon emissions and climate initiatives.
How Carbon Intensive is Jazz Pharmaceuticals (EUSA Pharma USA) Inc.'s Industry?
How Carbon Intensive is Jazz Pharmaceuticals (EUSA Pharma USA) Inc.'s Location?
Jazz Pharmaceuticals (EUSA Pharma USA) Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jazz Pharmaceuticals (EUSA Pharma USA) Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
